» Articles » PMID: 23713053

Failure of Anti-interleukin-1 Therapy in Severe Hidradenitis Suppurativa: a Case Report

Overview
Journal Dermatology
Publisher Karger
Specialty Dermatology
Date 2013 May 29
PMID 23713053
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hidradenitis suppurativa (HS) is an inflammatory, debilitating skin disease of follicular origin, characterized by painful deep-seated, inflamed lesions in mainly the inverse areas of the body. HS is notoriously difficult to treat and especially severe disease is often resistant to therapy. New therapeutic options are therefore highly needed. Elevated levels of IL-1 have been demonstrated in HS lesions. Here we report for the first time on the sequential treatment with anakinra (an IL-1 receptor antagonist) and golimumab (a TNF-α-neutralizing antibody) of a patient with severe HS and with comorbid psoriatic arthritis. Although adalimumab and golimumab were efficacious in improving arthritis complaints, both failed in improving the severe HS of our patient. Eventually the patient underwent radical excision of the inflammatory lesions and fistulas.

Citing Articles

Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective.

Heidari A, Ghane Y, Heidari N, Hosseini S, Goodarzi A Ther Adv Chronic Dis. 2024; 15:20406223241257342.

PMID: 38827348 PMC: 11143857. DOI: 10.1177/20406223241257342.


Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment.

Chu Y, Yu S Biomedicines. 2024; 12(2).

PMID: 38397941 PMC: 10886623. DOI: 10.3390/biomedicines12020338.


Hidradenitis suppurativa - biologic therapy and other available treatment options.

Lipa K, Zajac N, Witkowski G, Ciechanowicz P, Wiszniewski K, Szymanska E Postepy Dermatol Alergol. 2023; 40(4):518-528.

PMID: 37692279 PMC: 10485753. DOI: 10.5114/ada.2021.112075.


Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.

Fragoso N, Masson R, Gillenwater T, Shi V, Hsiao J Dermatol Ther (Heidelb). 2023; 13(8):1661-1697.

PMID: 37402031 PMC: 10366071. DOI: 10.1007/s13555-023-00956-6.


New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.

Molinelli E, Gioacchini H, Sapigni C, Diotallevi F, Brisigotti V, Rizzetto G Int J Mol Sci. 2023; 24(9).

PMID: 37176138 PMC: 10179439. DOI: 10.3390/ijms24098428.